| Autor: |
Monica Binaschi, Andrea Pellacani, Stefano Manzini, Christian Rohlff, Keith E. Wilson, Jonathan Terrett, Carmel M. Lynch, Michael Trang, Dee Aud, Rahel Awdew, Phuoc Huy Pham, James E. Ackroyd, Rachel L. Dusek, San Lin Lou, Nickolas Attanasio, Sudha Swaminathan, Uyen T. Do, Robert Boyd, Angelo Kaplan, Arnima Bisht, Joaquin Arribas, Cristina Bernadó Morales, Rosanna Manno, Rossana Bugianesi, Massimiliano Salerno, Daniela Bellarosa, Corrado Carrisi, Alessandro Bressan, Mario Bigioni, Alessio Fiascarelli, Giuseppe Merlino |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1535-7163.22506921.v1 |
| Popis: |
Supplementary Figure S2. In vitro characterization of MEN1309/OBT076. A) ELISA assay showed that both the unconjugated and DM4-conjugated antibodies were able to bind FcγRIIIA with the same affinity (n=2). B) FACS binding experiment on THP-1 cell line, performed by titrating unlabeled antibody with a constant amount of labelled antibody, showed high binding affinity of MBH1309/OBT076 to CD205 expressed on the cell surface with no affinity loss after conjugation (N=2). C) In vitro ADCC bioluminescence assay showed that, despite the ability to bind FcγRIIIA, MBH1309/OBT076 didn't induce any ADCC response. D) In vitro CDC assay on Raji cancer cell lines showed no CDC activity of MBH1309/OBT076 when incubated with purified human complement. On the contrary, Rituximab (used as positive control), showed a strong induction of CDC activity. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
